Marcus Peter, Ph.D. - 2008 Fletcher Scholar
Treatment of Cancer by Targeting its Embryonic Properties
Awarded the 2008 Fletcher Scholars Award
The biggest problem in cancer therapy is the ability of almost all human cancers to acquire resistance to all forms of chemo- or radiation therapy. One model describes cancer as cells that are exposed to environmental influences that reactivate cellular programs normally found in cells during embryonic development. According to this hypothesis, the process of tumor progression resembles that of a cell reversing to an embryonic state.
We recently identified a cellular component, a micro RNA called let-7, as a marker for more specialized cancer cells and found that it is lost during tumor progression in many human cancers. Let-7 has also been linked to resistance to both chemotherapy and radiation therapy, making it an attractive reagent to treat cancer. Additionally, we have discovered a set of twelve genes that are controlled by let-7 and now hypothesize that among this set of genes is a link between let-7 and the drug resistance that is observed in human cancer patients after chemotherapy. This proposal aims at identifying the genes that cause resistance to many forms of cancer therapy with the goal to identify novel targets for cancer treatment. Read more about Dr. Peter's proposal.
"I owe a great deal to the Cancer Research Foundation for giving me a head start. This financial help made the difference between my getting a fast and successful start, and my other wise struggling to obtain the necessary funds to get my research program started."Elaine Fuchs, Ph.D.
Professor, Departments of Medicine and Molecular Genetics and Cell Biology and Human Genetics University of Chicago
April 30, 2010